Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Karlsson · SciRah

Researcher profile · Semantic Scholar

C. Karlsson

Share profile

C. Karlsson — researcher profile on SciRah

h-index: 15
Works: 33
Citations: 1,328

Most-cited papers

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
A. Chanan-Khan, P. Cramer, F. Demirkan, G. Fraser +25 more
2016The Lancet Oncology407 citations
Semantic Scholar
Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia
J. Lundin, A. Porwit-Macdonald, E. Rossmann, C. Karlsson +5 more
2004Leukemia127 citations Open access
Semantic Scholar
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
M. Winqvist, A. Asklid, P. Andersson, K. Karlsson +8 more
2016Haematologica119 citations Open access
Semantic Scholar
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
D. Tamborero, R. Dienstmann, M. Rachid, J. Boekel +28 more
2022Nature Cancer117 citations Open access
Semantic Scholar
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
G. Fraser, P. Cramer, F. Demirkan, R. S. Silva +24 more
2018Leukemia117 citations Open access
Semantic Scholar
Strategies in the management of alemtuzumab-related side effects.
A. Osterborg, C. Karlsson, J. Lundin, E. Kimby +1 more
2006Seminars in Oncology62 citations
Semantic Scholar
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort
M. Winqvist, P. Andersson, A. Asklid, K. Karlsson +10 more
2018Haematologica61 citations Open access
Semantic Scholar
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody)
C. Karlsson, L. Hansson, F. Celsing, J. Lundin
2007Leukemia61 citations
Semantic Scholar
Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation
C. Karlsson, S. Norin, E. Kimby, B. Sander +6 more
2006Leukemia42 citations
Semantic Scholar
Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced‐stage, relapsed chronic lymphocytic leukaemia
C. Karlsson, J. Lundin, E. Kimby, B. Kennedy +3 more
2009British Journal of Haematology40 citations
Semantic Scholar
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
S. E. Sylvan, A. Asklid, H. Johansson, J. Klintman +13 more
2018Haematologica34 citations Open access
Semantic Scholar
Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine
Michele Masucci, C. Karlsson, Lennart Blomqvist, I. Ernberg
2024Journal of Personalized Medicine28 citations Open access
Semantic Scholar
Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia
A. Österborg, C. Karlsson, J. Lundin
2009Current Hematologic Malignancy Reports28 citations
Semantic Scholar
Reconstitution of the T‐cell repertoire following treatment with alemtuzumab (anti‐CD52 monoclonal antibody) in patients with B‐cell chronic lymphocytic leukaemia
M. Rezvany, M. Tehrani, C. Karlsson, J. Lundin +3 more
2006British Journal of Haematology23 citations Open access
Semantic Scholar
Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia
J. Lundin, C. Karlsson, F. Celsing
2006Medical Oncology17 citations
Semantic Scholar
Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region
Sandra Eketorp Sylvan, L. Hansson, C. Karlsson, S. Norin +2 more
2014Leukemia and Lymphoma11 citations
Semantic Scholar
The BioLymph study – implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results
K. Smedby, T. Wästerlid, E. Tham, Z. Haider +17 more
2023Acta oncologica7 citations Open access
Semantic Scholar
Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program
L. Hansson, M. Winqvist, A. Asklid, P. Andersson +8 more
20157 citations
Semantic Scholar
P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients
S. E. Sylvan, J. Lundin, M. Ipek, M. Palma +2 more
2014Journal of Immunotherapy for Cancer7 citations Open access
Semantic Scholar
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy‐induced immunosuppression
S. E. Sylvan, E. Rossmann, F. Mozaffari, A. Porwit +5 more
2012British Journal of Haematology5 citations
Semantic Scholar
Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
D. Tamborero, R. Dienstmann, M. Rachid, J. Boekel +28 more
2022Nature Cancer4 citations Open access
Semantic Scholar
Treatment of Refractory Autoimmune Hemolytic Anemia in B-CLL with Alemtuzumab (Humanized CD52 MAb).
J. Lundin, F. Celsing, C. Karlsson, A. Österborg
20054 citations
Semantic Scholar
Implementation of a Clinical Decision Support System for Precision Oncology across an Academic Network
D. Tamborero, R. Dienstmann, M. Rachid, J. Boekel +24 more
20211 citations Open access
Semantic Scholar
Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013
S. E. Sylvan, A. Asklid, H. Johansson, J. Klintman +13 more
20171 citations
Semantic Scholar
Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia
C. Karlsson, H. Dahl, J. Lundin, E. Rossmann +4 more
2011Blood Cancer Journal1 citations Open access
Semantic Scholar
Reconstitution of the T Cell Repertoire Following Treatment with Alemtuzumab in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL).
M. Rezvany, M. Tehrani, C. Karlsson, J. Lundin +3 more
20051 citations
Semantic Scholar
P609: EFFECT OF LONG-TERM ZANUBRUTINIB TREATMENT ON T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A STUDY CONDUCTED IN PARALLEL WITH THE BGB-3111-304 AND 305 TRIALS.
Maria L. Andersson, Tom Aadrian Mulder, K. Heimersson, Sonja Sönnert-Husa +6 more
2023HemaSphere0 citations Open access
Semantic Scholar
Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)—a single region experience on consecutive patients
S. E. Sylvan, J. Lundin, M. Ipek, M. Palma +2 more
2014Annals of Hematology0 citations
Semantic Scholar
Targeted therapy and outcome in chronic lymphocytic leukemia
A. Österborg, M. Höglund, J. Lundin, J. Samuelsson +4 more
20140 citations
Semantic Scholar
Targeted monoclonal antibody therapy in chronic lymphocytic leukemia
C. Karlsson
20100 citations
Semantic Scholar
From the Department of Oncology and Pathology Karolinska Institutet, Stockholm, Sweden Targeted monoclonal antibody therapy in chronic lymphocytic leukemia
C. Karlsson
20100 citations
Semantic Scholar
Onkologi-Patologi Targeted monoclonal antibody therapy in chronic lymphocytic leukemia
Akademisk Avhandling, C. Karlsson
20100 citations
Semantic Scholar
Virus Reactivation Profile as Assessed by PCR and Serology Pattern Following First-Line Alemtuzumab (Anti-CD52 Monoclonal Antibody, Campath®) Therapy in Patients with B-CLL.
C. Karlsson, H. Dahl, A. Linde, J. Lundin +3 more
20040 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Lundin×21
Invite
J. Lundin — researcher profile on SciRah
A. Österborg×19
Invite
A. Österborg — researcher profile on SciRah
L. Hansson×13
Invite
L. Hansson — researcher profile on SciRah
S. Norin×8
Invite
S. Norin — researcher profile on SciRah

×5

Invite

A. Asklid — researcher profile on SciRah

Invite

K. Karlsson — researcher profile on SciRah

Invite

B. Lauri — researcher profile on SciRah

Invite

M. Mattsson — researcher profile on SciRah

A. Sandstedt×5

Invite

A. Sandstedt — researcher profile on SciRah

Invite

E. Kimby — researcher profile on SciRah

H. Mellstedt×5

Invite

H. Mellstedt — researcher profile on SciRah

S. E. Sylvan×5

Invite

S. E. Sylvan — researcher profile on SciRah